309 related articles for article (PubMed ID: 24784368)
1. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma.
Mazonakis M; Berris T; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2014 May; 41(5):051702. PubMed ID: 24784368
[TBL] [Abstract][Full Text] [Related]
2. Radiation therapy for stage IIA and IIB testicular seminoma: peripheral dose calculations and risk assessments.
Mazonakis M; Berris T; Lyraraki E; Damilakis J
Phys Med Biol; 2015 Mar; 60(6):2375-89. PubMed ID: 25716274
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Mazonakis M; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2015 Nov; 42(11):6309-16. PubMed ID: 26520723
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk estimates from radiation therapy for heterotopic ossification prophylaxis after total hip arthroplasty.
Mazonakis M; Berris T; Lyraraki E; Damilakis J
Med Phys; 2013 Oct; 40(10):101702. PubMed ID: 24089892
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience.
Hallemeier CL; Pisansky TM; Davis BJ; Choo R
Urol Oncol; 2013 Nov; 31(8):1832-8. PubMed ID: 22537538
[TBL] [Abstract][Full Text] [Related]
7. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma.
Zwahlen DR; Martin JM; Millar JL; Schneider U
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):853-8. PubMed ID: 18164856
[TBL] [Abstract][Full Text] [Related]
8. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2018 Oct; 45(10):4775-4782. PubMed ID: 30105825
[TBL] [Abstract][Full Text] [Related]
9. Organ-specific radiation-induced cancer risk estimates due to radiotherapy for benign pigmented villonodular synovitis.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Phys Med Biol; 2016 Sep; 61(17):6400-12. PubMed ID: 27499236
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for non-malignant shoulder syndrome: Is there a risk for radiation-induced carcinogenesis?
Mazonakis M; Lyraraki E; Tzedakis A; Damilakis J
Phys Med; 2017 Nov; 43():73-78. PubMed ID: 29195566
[TBL] [Abstract][Full Text] [Related]
11. Second primary cancer in irradiated stage I testicular seminoma.
Stein ME; Steiner M; Lachter J; Kessel I; Moskovitz B; Kuten A
Strahlenther Onkol; 1993 Nov; 169(11):672-7. PubMed ID: 8248844
[TBL] [Abstract][Full Text] [Related]
12. Radiation-induced tumors in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968-1993).
Stein ME; Leviov M; Drumea K; Moshkovitz B; Nativ O; Milstein D; Sabo E; Kuten A
J Surg Oncol; 1998 Jan; 67(1):38-40. PubMed ID: 9457255
[TBL] [Abstract][Full Text] [Related]
13. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma.
Simone CB; Kramer K; O'Meara WP; Bekelman JE; Belard A; McDonough J; O'Connell J
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):242-9. PubMed ID: 21236595
[TBL] [Abstract][Full Text] [Related]
14. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes?
Bieri S; Rouzaud M; Miralbell R
Radiother Oncol; 1999 Mar; 50(3):349-53. PubMed ID: 10392822
[TBL] [Abstract][Full Text] [Related]
15. Peripheral organ doses from radiotherapy for heterotopic ossification of non-hip joints: is there a risk for radiation-induced malignancies?
Berris T; Mazonakis M; Kachris S; Damilakis J
Phys Med; 2014 May; 30(3):309-13. PubMed ID: 24084192
[TBL] [Abstract][Full Text] [Related]
16. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
17. Triple-rule-out computed tomography angiography with 256-slice computed tomography scanners: patient-specific assessment of radiation burden and associated cancer risk.
Perisinakis K; Seimenis I; Tzedakis A; Papadakis AE; Damilakis J
Invest Radiol; 2012 Feb; 47(2):109-15. PubMed ID: 21857528
[TBL] [Abstract][Full Text] [Related]
18. EVALUATION OF SECONDARY DOSE AND CANCER RISK FOR OUT-OF-FIELD ORGAN IN ESOPHAGEAL CANCER IMRT IN A CHINESE HOSPITAL USING ATOM PHANTOM MEASUREMENTS.
Qi Y; He L; Wang Z; Liu Y; Liu H; Huo W; Xu XG; Chen Z
Radiat Prot Dosimetry; 2017 Dec; 177(4):389-396. PubMed ID: 28472430
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk.
Efstathiou JA; Paly JJ; Lu HM; Athar BS; Moteabbed M; Niemierko A; Adams JA; Bekelman JE; Shipley WU; Zietman AL; Paganetti H
Radiother Oncol; 2012 Apr; 103(1):12-7. PubMed ID: 22391053
[TBL] [Abstract][Full Text] [Related]
20. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
Travis LB; Fosså SD; Schonfeld SJ; McMaster ML; Lynch CF; Storm H; Hall P; Holowaty E; Andersen A; Pukkala E; Andersson M; Kaijser M; Gospodarowicz M; Joensuu T; Cohen RJ; Boice JD; Dores GM; Gilbert ES
J Natl Cancer Inst; 2005 Sep; 97(18):1354-65. PubMed ID: 16174857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
